STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 188956

TO: Marcela Cordero Garcia **Location: REM/3A30/3C18** **Art Unit: 1654** **Thursday, May 11, 2006** **Case Serial Number: 10/723144**	**From: Noble Jarrell** **Location: Biotech-Chem Library** **Rem 1B71** **Phone: 272-2556** **Noble.jarrell@uspto.gov**

Search Notes

NOBLE JARREL
(RAN ORIGINAL SRCH) ACCESS DB # 188966

FOR OFFICIAL USE ONLY PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARCELA M CORDERO GARCIA Examiner #: 80381 Date: 5/5/06
Art Unit: 1654 Phone Number: 2-2939 Serial Number: 10/723,144
Location (Bldg/Room#): REM3A30 (Mailbox #): 3C18 Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: SEE BIB DS

Inventors (please provide full names): SEE BIB DS

Earliest Priority Date: 11/02

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

PLEASE UPDATE SRCH FOR ALLOWANCE:



R_1 = acyl, substituted acyl, oxycarbonyl & substituted oxycarbonyl

R_2 = alkyl, $-(CH_2)_m S(O)_n R^5$ or $-(CH_2)_m S(O)_n - S(O)_o R^5$

$m = 1$ or 2, n & $o = 0, 1$ or 2

R_5 = OPEN (can be alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylakyl, subst. heteroarylalkyl, oxycarbonyl, substituted oxycarbonyl)

****

STAFF USE ONLY

Searcher: Noble
Searcher Phone #:
Searcher Location:
Date Searcher Picked Up: 5/11/06
Date Completed: 5/11/06
Searcher Prep & Review Time: 15
Online Time: 25

Type of Search

___ NA Sequence (#)
___ AA Sequence (#)
1 Structure (#)
✓ Bibliographic
___ Litigation
___ Fulltext
___ Other

Vendors and cost where applicable

✓ STN ___ Dialog
___ Questel/Orbit ___ Lexis/Nexis
___ Westlaw ___ WWW/Internet
___ In-house sequence systems
___ Commercial ___ Oligomer ___ Score/Length
___ Interference ___ SPDI ___ Encode/Transl
___ Other (specify)

```
=> b reg
FILE 'REGISTRY' ENTERED AT 07:01:43 ON 11 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     9 MAY 2006  HIGHEST RN 883631-57-0
DICTIONARY FILE UPDATES:    9 MAY 2006  HIGHEST RN 883631-57-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l24
L22             STR
```




```
REP G1=(0-1) 38
NODE ATTRIBUTES:
CONNECT IS M1  RC AT   1
CONNECT IS M1  RC AT  12
CONNECT IS M1  RC AT  38
DEFAULT MLEVEL IS ATOM
```

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 27
NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE
L24 64 SEA FILE=REGISTRY CSS FUL L22

100.0% PROCESSED 33412 ITERATIONS 64 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 07:01:56 ON 11 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 May 2006 VOL 144 ISS 20
FILE LAST UPDATED: 9 May 2006 (20060509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitstr l26 tot

L26 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:610128 HCAPLUS
DN 141:157478
ED Entered STN: 30 Jul 2004
TI Peptides which target tumor and endothelial cells, compositions and uses thereof
IN **Allan, Amy L.; Yoon, Won Hyung; Gladstone, Patricia L.; Ternansky, Robert J.; Parry, Graham; Donate, Fernando; Mazar, Andrew**
PA **Attenuon, Llc, USA**
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004063213	A2	20040729	2003WO-US37895	20031125 <--
	WO2004063213	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR; BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA---2506813	AA	20040729	2003CA-2506813	20031125	<--
US2004162239	A1	20040819	2003US-0723144	20031125	<--
US2005020810	A1	20050127	2003US-0722843	20031125	<--
EP---1569678	A2	20050907	2003EP-0796483	20031125	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR2003016550	A	20051004	2003BR-0016550	20031125	<--
CN---1741808	A	20060301	CN 2003-80109204	20031125	<--
CN---1741809	A	20060301	CN 2003-80109205	20031125	<--
NO2005003112	A	20050805	2005NO-0003112	20050624	<--
PRAI 2002US-429174P	P	20021125	<--		
2003US-475539P	P	20030602	<--		
2003WO-US37895	W	20031125			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004063213	ICM	C07K
	IPCI	C07K [ICM,7]
	IPCR	A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00 [I,C]; C07K0007-08 [I,A]
	ECLA	C07K007/06A
CA---2506813	IPCI	A61K0038-10 [ICM,7]; C07K0007-06 [ICS,7]; A61K0038-08 [ICS,7]; C07K0007-08 [ICS,7]; C07K0007-00 [ICS,7]
	IPCR	A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00 [I,C]; C07K0007-08 [I,A]
	ECLA	C07K007/06A
US2004162239	IPCI	A61K0038-08 [ICM,7]; A61K0038-10 [ICS,7]; C07K0007-08 [ICS,7]; C07K0007-06 [ICS,7]; C07K0007-00 [ICS,7]
	IPCR	A61K0038-08 [I,A]; A61K0038-08 [I,C]; A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00 [I,C]; C07K0007-06 [I,A]; C07K0007-08 [I,A]
	NCL	514/012.000
US2005020810	IPCI	C07K0007-08 [ICM,7]; C07K0007-06 [ICS,7]; C07K0007-00 [ICS,7]
	IPCR	C07K0007-00 [I,C]; C07K0007-06 [I,A]; C07K0007-08 [I,A]
	NCL	530/324.000
EP---1569678	IPCI	A61K0038-10 [ICM,7]; A61K0038-08 [ICS,7]; C07K0007-08 [ICS,7]; C07K0007-06 [ICS,7]; C07K0007-00 [ICS,7]
	IPCR	A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00 [I,C]; C07K0007-08 [I,A]
	ECLA	C07K007/06A
BR2003016550	IPCI	A61K0038-10 [ICM,7]; A61K0038-08 [ICS,7]; C07K0007-08 [ICS,7]; C07K0007-06 [ICS,7]; C07K0007-00 [ICS,7]
	IPCR	A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00 [I,C]; C07K0007-08 [I,A]
	ECLA	C07K007/06A
CN---1741808	IPCI	A61K0038-10 [I,A]; A61K0038-08 [I,A]; C07K0007-06 [I,A]; C07K0007-08 [I,A]; C07K0007-00 [I,C]
CN---1741809	IPCI	A61K0038-10 [I,A]; A61K0038-08 [I,A]; C07K0007-08 [I,A]; C07K0007-06 [I,A]; C07K0007-00 [I,C]
NO2005003112	IPCI	A61K0038-04 [ICM,7]; C07K0007-08 [ICS,7]; C07K0007-06 [ICS,7]; C07K0007-00 [ICS,7]
	ECLA	C07K007/06A

OS MARPAT 141:157478

AB The invention relates generally to peptide analogs of Ac-PHSCN-NH2 which target tumor and endothelial cells and have antitumor, antiangiogenic and antimetastatic activity and to methods for their synthesis and use in pharmaceutical compns. for treating, preventing and detecting diseases characterized by tumor growth, metastasis and angiogenesis. The peptide

analogs may serve, inter alia, as carriers of radioactivity, PET-active compds., toxins, fluorescent mols. and PEG mols. Peptides R1[(NHCHR2CO)0-1(X1)0-100]m-X2-X3-X4-X5-X6-[(X7)0-1(NHCHR3CO)0-1]nNR4R5 [R1 is (un)substituted acyl, alkyl, cycloalkyl or imino, or acyl chelate; R2 is substituted alkyl; R4, R5 are (un)substituted alkyl; X1, X7 are NH(CH:CH)1-6CO, NH(CH2)1-6CO, NHCHMeCO; X2-X6 are α-amino acids which are defined; m, n are 0 or 1, with the proviso that R1 is not acetyl when R4 and R5 are H and m and n are 0] are claimed. Thus, Ac-Pro-His-Ser-Cys(Ac)-Asn-OH was prepared by the solid-phase method and coupled to doxorubicin hydrochloride to afford the conjugate.

ST peptide prolylhistidylserylcysteinylaspartamide analog prepn antitumor

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Neoplasm
(preparation of peptides which target tumor and endothelial cells)

IT Peptides, preparation
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT Polyoxyalkylenes, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides which target tumor and endothelial cells)

IT 729594-60-9P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT 7440-74-6DP, Indium, complexes with DPTA peptide conjugate
262438-43-7DP, analogs **729594-61-0P** 729594-62-1P
729594-63-2P **729594-64-3P** 729594-65-4P **729594-66-5P**
729594-67-6P **729594-68-7P** **729594-69-8P**
729594-70-1P 729594-71-2P 729594-72-3P 729594-73-4P
729594-74-5P 729594-75-6P 729594-76-7P 729594-77-8P
729594-78-9P 729594-79-0P 729594-80-3P 729594-81-4P
729594-82-5P **729594-83-6P** 729594-84-7P
729594-85-8P **729594-86-9P** 729594-87-0P
729594-88-1P 729594-89-2P **729594-90-5P** 729594-91-6P
729594-92-7P 729594-93-8P **729594-94-9P**
729594-95-0P **729594-96-1P** **729594-97-2P**
729594-98-3P 729594-99-4P 729595-00-0P **729595-01-1P**
729595-02-2P 729595-03-3DP, polyethylene glycol derivative
729595-04-4P **729595-05-5P** 729595-06-6P 729595-07-7P
729595-08-8P **729595-09-9P** 729595-14-6P **730960-54-0P**
731003-01-3DP, Indium complexes **731003-01-3P**
731003-02-4P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)

IT 456-22-4, 4 Fluorobenzoic acid 501-97-3 553-12-8 3301-79-9, 6 Carboxyfluorescein 13811-11-5 25316-40-9, Doxorubicin hydrochloride 34071-95-9 66134-67-6 76823-03-5, 5 Carboxyfluorescein 106966-68-1 137076-54-1, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris 1 1 dimethylethyl ester 517913-89-2 622405-78-1 729595-15-7 **729595-16-8D**, resin-bound 729595-17-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides which target tumor and endothelial cells)

IT 729595-10-2DP, resin-bound 729595-11-3DP, resin-bound 729595-12-4DP, resin-bound 729595-13-5DP, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides which target tumor and endothelial cells)

IT **262438-43-7DP**, analogs
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides which target tumor and endothelial cells)
RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:467702 HCAPLUS
DN 141:33798
ED Entered STN: 10 Jun 2004
TI Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, their preparation, and compositions and therapeutic uses thereof
IN **Allan, Amy L.; Donate, Fernando; Hopkins, Stephanie A.; Gladstone, Patricia L.; Mazar, Andrew ; O'Hare, Sean M.; Parry, Graham; Plunkett, Marian L.; Ternansky, Robert J.; Yoon, Won Hyung**
PA **Attenuon, LLC, USA**
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-8 (Pharmacology)
Section cross-reference(s): 34, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004047771	A2	20040610	2003WO-US38175	20031125 <--
	WO2004047771	A3	20050915		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2507045	AA	20040610	2003CA-2507045	20031125 <--
	US2004162239	A1	20040819	2003US-0723144	20031125 <--
	US2005020810	A1	20050127	2003US-0722843	20031125 <--
	BR2003016523	A	20051018	2003BR-0016523	20031125 <--
	EP---1594521	A2	20051116	2003EP-0812058	20031125 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN---1741808	A	20060301	CN 2003-80109204	20031125 <--
	CN---1741809	A	20060301	CN 2003-80109205	20031125 <--
	JP2006514116	T2	20060427	2005JP-0510345	20031125 <--

```
     NO2005003111          A      20050824    2005NO-0003111         20050624 <--
PRAI 2002US-429174P        P      20021125  <--
     2003US-475539P        P      20030602  <--
     2003WO-US38175        W      20031125
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2004047771    ICM    A61K
                  IPCI   A61K [ICM,7]
                  IPCR   A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00
                         [I,C]; C07K0007-08 [I,A]
                  ECLA   C07K007/06A
 CA---2507045     IPCI   C07K0007-06 [ICM,7]; C07K0007-00 [ICM,7]; A61P0035-00
                         [ICS,7]; A61K0038-05 [ICS,7]; A61K0038-06 [ICS,7];
                         C07K0005-06 [ICS,7]; A61K0038-07 [ICS,7]; A61K0038-08
                         [ICS,7]; C07K0005-08 [ICS,7]; C07K0005-10 [ICS,7];
                         C07K0005-00 [ICS,7]
                  IPCR   A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00
                         [I,C]; C07K0007-08 [I,A]
                  ECLA   C07K007/06A
 US2004162239     IPCI   A61K0038-08 [ICM,7]; A61K0038-10 [ICS,7]; C07K0007-08
                         [ICS,7]; C07K0007-06 [ICS,7]; C07K0007-00 [ICS,7]
                  IPCR   A61K0038-08 [I,A]; A61K0038-08 [I,C]; A61K0038-10
                         [I,A]; A61K0038-10 [I,C]; C07K0007-00 [I,C];
                         C07K0007-06 [I,A]; C07K0007-08 [I,A]
                  NCL    514/012.000
 US2005020810     IPCI   C07K0007-08 [ICM,7]; C07K0007-06 [ICS,7]; C07K0007-00
                         [ICS,7]
                  IPCR   C07K0007-00 [I,C]; C07K0007-06 [I,A]; C07K0007-08 [I,A]
                  NCL    530/324.000
 BR2003016523     IPCI   A61K0038-10 [ICM,7]; A61K0038-08 [ICS,7]; C07K0007-08
                         [ICS,7]; C07K0007-06 [ICS,7]; C07K0007-00 [ICS,7]
                  IPCR   A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00
                         [I,C]; C07K0007-08 [I,A]
                  ECLA   C07K007/06A
 EP---1594521     IPCI   A61K0038-10 [ICM,7]; A61K0038-08 [ICS,7]; C07K0007-06
                         [ICS,7]; C07K0007-08 [ICS,7]; C07K0007-00 [ICS,7]
                  IPCR   A61K0038-10 [I,A]; A61K0038-10 [I,C]; C07K0007-00
                         [I,C]; C07K0007-08 [I,A]
                  ECLA   C07K007/06A
 CN---1741808     IPCI   A61K0038-10 [I,A]; A61K0038-08 [I,A]; C07K0007-06
                         [I,A]; C07K0007-08 [I,A]; C07K0007-00 [I,C]
 CN---1741809     IPCI   A61K0038-10 [I,A]; A61K0038-08 [I,A]; C07K0007-08
                         [I,A]; C07K0007-06 [I,A]; C07K0007-00 [I,C]
 JP2006514116     IPCI   C07K0005-06 [I,A]; A61K0038-00 [I,A]; A61P0035-00
                         [I,A]; A61K0045-00 [I,A]; C07K0005-097 [I,A];
                         C07K0005-117 [I,A]; C07K0005-00 [I,C]; C07K0007-06
                         [I,A]; C07K0007-00 [I,C]
                  FTERM  4C084/AA02; 4C084/AA07; 4C084/AA19; 4C084/BA01;
                         4C084/BA08; 4C084/BA14; 4C084/BA15; 4C084/BA16;
                         4C084/BA32; 4C084/CA59; 4C084/DA25; 4C084/DB57;
                         4C084/NA14; 4C084/ZB261; 4C084/ZB262; 4C084/ZC751;
                         4H045/AA10; 4H045/AA20; 4H045/AA30; 4H045/BA11;
                         4H045/BA12; 4H045/BA13; 4H045/CA40; 4H045/EA20;
                         4H045/FA33; 4H045/FA41; 4H045/GA25
 NO2005003111     IPCI   C07K [ICM,7]
                  ECLA   C07K007/06A
OS   MARPAT 141:33798
AB   The invention discloses peptides which inhibit angiogenesis, cell
     migration, cell invasion and cell proliferation, as well as methods of
     making the peptides, pharmaceutical compns. containing the peptides, and
     methods of using the peptides and pharmaceutical compns. to treat diseases
     associated with aberrant vascularization, e.g. cancer.
ST   peptide cell invasion migration proliferation inhibition; antitumor
     aberrant vascularization disease peptide prepn
IT   Sarcoma
```

(cartilage chondrosarcoma; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Cartilage, neoplasm
(chondrosarcoma; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Intestine, neoplasm
(colon; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Blood vessel
(endothelium; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Blood vessel, neoplasm
Sarcoma
(hemangiosarcoma; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Brain, neoplasm
Drug delivery systems
Kidney, neoplasm
Mammary gland, neoplasm
Neoplasm
Prostate gland, neoplasm
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT Endothelium
(vascular; peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 701201-26-5D, biotinylated
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT **701200-82-0P 701201-01-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 81658-55-1P **701200-81-9P 701200-83-1P**
701200-84-2P 701200-85-3P 701200-86-4P 701200-87-5P
701200-88-6P 701200-89-7P **701200-90-0P**
701200-91-1P 701200-92-2P 701200-93-3P
701200-94-4P 701200-95-5P 701200-96-6P 701200-97-7P 701200-98-8P
701200-99-9P 701201-00-5P 701201-02-7P
701201-03-8P 701201-04-9P 701201-05-0P
701201-06-1P 701201-07-2P 701201-08-3P
701201-09-4P 701201-10-7P 701201-11-8P
701201-12-9P 701201-13-0P 701201-14-1P
701201-15-2P 701201-16-3P 701201-17-4P
701201-18-5P 701201-19-6P 701201-20-9P
701201-21-0P 701201-22-1P 701201-23-2P **701201-24-3P**
701201-25-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 701201-28-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT 98-88-4, Benzoyl chloride 100-39-0, Benzyl bromide 106-95-6, Allyl bromide, reactions 930-69-8 1212-08-4, S-Phenyl benzenethiosulfonate 2719-27-9, Cyclohexanoyl chloride 2937-50-0, Allyl chloroformate 2949-92-0, S-Methyl methanethiosulfonate 3282-30-2, Pivaloyl chloride 5271-67-0, 2-Thiophenecarbonyl chloride 6482-24-2, 2-Bromoethyl methylether 7031-27-8, (Phenylthio)acetyl chloride 10400-19-8, Nicotinoyl chloride 25644-88-6, S-Benzyl-L-cysteine sulfone 82911-69-1 **262438-43-7** 475150-36-8 701201-27-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

IT **701200-82-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)

RN 701200-82-0 HCAPLUS

CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-[(4-methylphenyl)methyl]-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L26 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:243058 HCAPLUS
DN 139:173332
ED Entered STN: 30 Mar 2003
TI Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice
AU Stoeltzing, Oliver; Liu, Wenbiao; Reinmuth, Niels; Fan, Fan; **Parry, Graham C.**; Parikh, Alexander A.; McCarty, Marya F.; Bucana, Corazon D.; **Mazar, Andrew P.**; Ellis, Lee M.
CS Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030-4009, USA
SO International Journal of Cancer (2003), 104(4), 496-503
CODEN: IJCNAW; ISSN: 0020-7136
PB Wiley-Liss, Inc.
DT Journal
LA English
CC 1-6 (Pharmacology)

AB Integrin α5β1 is expressed on activated endothelial cells and plays a critical role in tumor angiogenesis. We hypothesized that a novel integrin α5β1 antagonist, ATN-161, would inhibit angiogenesis and growth of liver metastases in a murine model. We further hypothesized that combining ATN-161 with 5-fluorouracil (5-FU) chemotherapy would enhance the antineoplastic effect. Murine colon cancer cells (CT26) were injected into spleens of BALB/c mice to produce liver metastases. Four days thereafter, mice were given either ATN-161 (100 mg/kg, every 3rd day) or saline by i.p. injection, with or without combination of continuous-infusion 5-FU (100 mg/kg/2 wk), which was started on day 7. On day 20 after tumor cell inoculation, mice were killed and liver wts. and number of liver metastases were determined A follow-up study on survival was also conducted in which mice were randomized to receive ATN-161, 5-FU or ATN-161+5-FU. Combination therapy with ATN-161+5-FU significantly reduced tumor burden (liver weight) and number of liver metastases ($p<0.02$). Liver tumors in the ATN-161 and ATN-161+5-FU groups had significantly fewer microvessels ($p<0.05$) than tumors in the control or 5-FU-treated groups. Unlike treatment with either agent alone, ATN-161+5-FU significantly increased tumor cell apoptosis and decreased tumor cell proliferation ($p<0.03$) and improved overall survival ($p<0.03$, log-rank test). Targeting integrin α5β1 in combination with 5-FU infusion reduced liver metastases formation and improved survival in this colon cancer model. The enhancement of antineoplastic activity from the combination of anti-angiogenic therapy and chemotherapy may be a promising approach for treating metastatic colorectal cancer.

ST ATN 161 fluorouracil colorectal cancer integrin

IT Intestine, neoplasm
(colorectal; inhibition of integrin α5β1 function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

IT Liver, neoplasm
(metastasis; inhibition of integrin α5β1 function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

IT Drug interactions
(synergistic; inhibition of integrin α5β1 function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α5β1; inhibition of integrin α5β1 function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

IT **262438-43-7**, ATN 161
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of integrin α5β1 function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

IT 51-21-8, 5-Fluorouracil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of integrin α5β1 function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Baker, C; Cancer Res 2002, V62, P1996 HCAPLUS
(2) Bello, L; Cancer Res 2001, V61, P7501 HCAPLUS
(3) Bergsland, E; Proc Am Soc Clin Oncol 2000, V19, P242
(4) Braakhuis, B; Semin Oncol 1995, V22, P42 HCAPLUS
(5) Brooks, P; Cell 1994, V79, P1157 HCAPLUS
(6) Brooks, P; J Clin Invest 1995, V96, P1815 HCAPLUS
(7) Browder, T; Cancer Res 2000, V60, P1878 HCAPLUS
(8) Bruns, C; Cancer 2000, V89, P488 HCAPLUS
(9) Bruns, C; Clin Cancer Res 2000, V6, P1936 HCAPLUS

(10) Fidler, I; Cancer Metastasis Rev 1991, V10, P229 MEDLINE
(11) Friedlander, M; Science 1995, V270, P1500 HCAPLUS
(12) Gately, S; Cancer J 2001, V7, P427 MEDLINE
(13) Giancotti, F; Science 1999, V285, P1028 HCAPLUS
(14) Gong, J; Cell Growth Differ 1997, V8, P83 HCAPLUS
(15) Griggs, D; Proc Am Assoc Cancer Res 2001, V42, P1420
(16) Hanahan, D; J Clin Invest 2000, V105, P1045 HCAPLUS
(17) Hynes, R; Cell 1992, V69, P11 HCAPLUS
(18) Kakeji, Y; Invest New Drugs 1997, V15, P39 HCAPLUS
(19) Kase, S; Anticancer Res 1993, V13, P369 HCAPLUS
(20) Kerbel, R; Ann Oncol 2002, V13, P12 MEDLINE
(21) Kerbel, R; Eur J Cancer 2000, V36, P1248 HCAPLUS
(22) Kerr, J; Anticancer Res 1999, V19, P959 HCAPLUS
(23) Kerr, J; Expert Opin Investig Drugs 2000, V9, P1271 HCAPLUS
(24) Kim, S; Am J Pathol 2000, V156, P1345 HCAPLUS
(25) Kim, S; J Biol Chem 2000, V275, P33920 HCAPLUS
(26) Klement, G; Clin Cancer Res 2002, V8, P221 HCAPLUS
(27) Klement, G; J Clin Invest 2000, V105, PR15 HCAPLUS
(28) Klotz, O; Arch Clin Exp Ophthalmol 2000, V238, P88 HCAPLUS
(29) Kumar, C; Adv Exp Med Biol 2000, V476, P169 MEDLINE
(30) Kumar, C; Cancer Res 2001, V61, P2232 HCAPLUS
(31) Livant, D; Cancer Res 2000, V60, P309 HCAPLUS
(32) Lode, H; Proc Natl Acad Sci USA 1999, V96, P1591 HCAPLUS
(33) Morikawa, K; J Natl Cancer Inst 1990, V82, P517 HCAPLUS
(34) Mross, K; Drug Resist Updat 2000, V3, P223 HCAPLUS
(35) O'Brien, V; Exp Cell Res 1996, V224, P208 HCAPLUS
(36) Remmenga, S; Gynecol Oncol 1994, V55, P115 MEDLINE
(37) Schreiner, C; Clin Exp Metastasis 1991, V9, P163 HCAPLUS
(38) Stoeltzing, O; Clin Cancer Res 2001, V7, P3656S
(39) Storgard, C; J Clin Invest 1999, V103, P47 HCAPLUS
(40) Tedjarati, S; Clin Cancer Res 2002, V8, P2413 HCAPLUS
(41) Varner, J; Mol Biol Cell 1995, V6, P725 HCAPLUS
(42) White, E; J Immunol 2001, V167, P5362 HCAPLUS

IT **262438-43-7**, ATN 161
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of integrin α5β1 function with ATN-161 plus 5-FU infusion reduces colorectal liver metastases and improves survival in mice)

RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr l27 tot

L27 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:303191 HCAPLUS
DN 142:341966
ED Entered STN: 08 Apr 2005
TI Hydrogels used to deliver medicaments to the eye for the treatment of

posterior segment diseases
IN Schultz, Clyde L.
PA USA
SO U.S. Pat. Appl. Publ., 7 pp., Cont.-in-part of U.S. Ser. No. 821,718.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K-0039/395
ICS A61K-0038/24; A61K-0031/65; A61K-0009/14; A61K-0031/56; A61K-0031/075
INCL 424486000; 514008000; 514012000; 424144100; 514182000; 514721000; 514152000
CC 63-6 (Pharmaceuticals)
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US2005074497	A1	20050407	2004US-0971997	20041022
US2005208102	A1	20050922	2004US-0821718	20040409
US2005255144	A1	20051117	2005US-0102454	20050409
WO2005110473	A2	20051124	2005WO-US12185	20050409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI 2003US-461354P	P	20030409
2004US-0821718	A2	20040409
2004US-0971997	A2	20041022

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005074497	ICM	A61K-0039/395
	ICS	A61K-0038/24; A61K-0031/65; A61K-0009/14; A61K-0031/56; A61K-0031/075
	INCL	424486000; 514008000; 514012000; 424144100; 514182000; 514721000; 514152000
	IPCI	A61K0039-395 [ICM,7]; A61K0038-24 [ICS,7]; A61K0031-65 [ICS,7]; A61K0009-14 [ICS,7]; A61K0031-56 [ICS,7]; A61K0031-075 [ICS,7]
	IPCR	A61K0031-075 [I,A]; A61K0031-075 [I,C]; A61K0031-56 [I,A]; A61K0031-56 [I,C]; A61K0031-65 [I,A]; A61K0031-65 [I,C]
	NCL	424/486.000
	ECLA	A61K031/075; A61K031/56; A61K031/65
US2005208102	IPCI	A61F0002-00 [ICM,7]; A61K0009-14 [ICS,7]
	IPCR	A61K0031-075 [I,A]; A61K0031-075 [I,C]; A61K0031-56 [I,A]; A61K0031-56 [I,C]; A61K0031-65 [I,A]; A61K0031-65 [I,C]
	NCL	424/427.000
	ECLA	A61K031/075; A61K031/56; A61K031/65
US2005255144	IPCI	A61F0002-00 [ICM,7]
	IPCR	A61F0002-00 [I,A]; A61F0002-00 [I,C]
	NCL	424/428.000
WO2005110473	IPCI	A61K0039-395 [ICM,7]; A61K0038-24 [ICS,7]; A61K0031-65 [ICS,7]; A61K0009-14 [ICS,7]; A61K0031-56 [ICS,7]; A61K0031-075 [ICS,7]

AB This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Exemplary drugs are anti-angiogenesis compds. for the treatment of macular degeneration. Allowing passive transference of this drug from

a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concns. of compds., e.g., from eye drops.

ST hydrogel drug ophthalmic posterior segment delivery; angiogenesis inhibitor hydrogel eye macular degeneration treatment

IT Thrombospondins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(1; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Platelet-derived growth factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BB; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Transcription factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HIF-1α (hypoxia-inducible factor 1α); hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Polysaccharides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PS-K; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VEGF trap; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Calreticulin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino-terminal fragment (vasostatin); hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Growth factors, animal
Platelet-derived growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Epidermal growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Tea products
(green; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Angiogenesis inhibitors
Calcium channel blockers
Contact lenses
Cytotoxic agents
Human
Hydrogels
Sodium channel blockers
Viral vectors
Vision
(hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT CD59 (antigen)
Fibronectins
Hepatocyte growth factor
Interleukin 12
Interleukin 8

Macrophage inflammatory protein 2α
Midkines
Pleiotrophins
Retinoids
Tetracyclines
Tumor necrosis factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interferon γ-inducible protein-10, upregulators; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interferon-induced; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Eye, disease
(macula, degeneration, treatment of; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, anti-VEGF Mab; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Antibodies and Immunoglobulins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, conjugates, with DOTA and radiolabeled; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Drug delivery systems
(ophthalmic; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-2a; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Transforming growth factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α5β1, antibody; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Transforming growth factors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β-; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(β; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 99519-84-3, CAI
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CAI; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 212142-18-2, PTK 787
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PTK 787; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 92769-12-5, Proliferin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Proliferin; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 106096-92-8, AFGF
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aFGF; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 127464-60-2, VEGF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 50-35-1, Thalidomide 52-67-5, Penicillamine 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 1861-40-1, Benefin 7559-04-8, Metarene 7753-60-8, Anecortave acetate 9000-94-6, Antithrombin 9002-61-3, Choriogonadotropin 9002-62-4, Prolactin, biological studies 9005-49-6D, Heparin, fragments, biological studies 9025-39-2, Heparinase 9030-23-3, Plateletderived endothelial cell growth factor 10098-91-6D, Yttrium-90, mAbJ591-DOTA conjugates, labeled with, biological studies 10540-29-1, Tamoxifen 15866-90-7, Col-3 16330-92-0 19171-19-8, Actimid 21416-67-1, Razoxane 24584-09-6, Dexrazoxane 33069-62-4, Paclitaxel 37270-94-3, Platelet factor-4 37300-21-3, Pentosan polysulfate 38101-59-6, IM862 58798-73-5, Tetrahydrocortisol sulfate 59973-80-7, Aptosyn 60239-18-1D, DOTA, conjugates with mAbJ591, radiolabeled 62031-54-3, FGF 64224-21-1, Oltipraz 75706-12-6, SU101 77327-05-0, Didemnin B 82855-09-2, Combretastatin 83150-76-9, Octreotide 86090-08-6, Angiostatin 86102-31-0, TIMP 98724-27-7, Proliferin-related protein 105844-41-5, Plasminogen activator inhibitor 106096-93-9, BFGF 112953-11-4, UCN-01 117570-53-3, DMXAA 117628-82-7, Follistatin 120685-11-2, PKC 412 123584-45-2, Fibroblast growth factor 4 125313-92-0, Ro31-7453 129298-91-5, TNP-470 134633-29-7, Tecogalan sodium 137219-37-5, Aplidine 139316-59-9, Progranulin 143011-72-7, Granulocyte colonystimulating factor 144697-25-6 144941-41-3, Placental ribonuclease inhibitor 145266-99-5 146426-40-6, Flavopiridol 148717-90-2, Squalamine 154039-60-8, Marimastat 162011-90-7, Vioxx 169494-85-3, Leptin 169590-42-5, Celebrex 169939-94-0, LY-333531 179545-77-8, Bay 12-9566 181427-78-1, NM-3 184475-35-2, Iressa 185077-23-0, PI 88 186270-49-5, Angiopoietin 1 187888-07-9, Endostatin 188417-67-6, CM 101 (polysaccharide) 188968-51-6, Cilengitide 191732-72-6, CC 5013 192329-42-3, AG3340 192819-27-5, CDC801 197980-93-1, Pigment epithelium-derived factor 204005-46-9, SU5416 216974-75-3, Avastin 219923-05-4, ZD6126 220420-78-0, Angiozyme 222030-63-9 222716-86-1, Pegaptanib sodium 252003-65-9, CP-547632 252916-29-3, SU6668 253426-24-3, AVE8062 262438-43-7, ATN-161 303127-73-3, Medi-522 305838-77-1, Neovastat 324740-00-3, Vitaxin 339152-98-6, ABX-IL 8 347396-82-1, Ranibizumab 352423-07-5, Placental growth factor

365253-37-8, LY317615 402857-58-3, CEP-7055 443912-16-1, CC 7085
443913-73-3, ZD6474 445467-72-1, ABT-510 557795-02-5, CP 564959
564490-65-9 572921-97-2, Angiogenin 848784-95-2, AMG 001
848784-98-5, MS 275291 848785-21-7, GBC 100 848785-35-3, ISV 120
848785-37-5, Angioarrestin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 9003-07-0, Polypropylene 9004-34-6D, Cellulose, oxidized, regenerated 26009-03-0, Polyglycolic acid 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26124-68-5, Polyglycolic acid 26161-42-2 26680-10-4, Polylactide 26780-50-7, Polyglactin 910 29223-92-5, Poly-p-dioxanone 30846-39-0, Poly(L-lactidecoglycolide) 31621-87-1, Polydioxanone 33135-50-1, Poly(L-lactide) 35528-20-2, Vifilcon A 56551-60-1, Lidofilcon A 61463-79-4, Etafilcon A 114959-05-6, Poly-4-hydroxybutyrate 618109-09-4, Polymacon B 618109-14-1, Vasurfilcon A
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT 141436-78-4, Protein kinase C
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; hydrogels containing drugs for treatment of eye diseases in posterior segment)

IT **262438-43-7**, ATN-161
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogels containing drugs for treatment of eye diseases in posterior segment)

RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:692596 HCAPLUS
DN 138:90056
ED Entered STN: 13 Sep 2002
TI Design and synthesis of the hydroxamic acid variants antitumorigenic and antimetastatic hydroxamate based Ac-PHSXX'-NH2 sequences
AU Sun, Yingchuan; Spatola, Arno F.
CS Department of Chemistry and the Institute for Molecular Diversity and Drug Design, University of Louisville, Louisville, KY, 40292, USA
SO Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001 (2001), 799-800. Editor(s): Lebl, Michal; Houghten, Richard A. Publisher: American Peptide Society, San Diego, Calif.
CODEN: 69DBAL; ISBN: 0-9715560-0-8
DT Conference
LA English
CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1
AB A symposium report. Peptides MeCO-Pro-His-Ser-Xaa-Yaa-NH2 [Xaa = Asp(NHOH), Glu(NHOH); Yaa = Leu, Asn], containing a hydroxamate group for superior metal-binding ability, were synthesized as potential antitumor and antimetastatic agents (biol. activity data not reported).
ST peptide hydroxamate prepn potential antitumor agent symposium
IT Antitumor agents
Neoplasm
(preparation of peptidyl hydroxamic acids as potential antitumor and antimetastatic agents)
IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of peptidyl hydroxamic acids as potential antitumor and antimetastatic agents)
IT 483369-69-3P **483369-70-6P 483369-71-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of peptidyl hydroxamic acids as potential antitumor and antimetastatic agents)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aota, S; J Biol Chem 1994, V269, P24756 HCAPLUS
(2) Chen, J; Tetrahedron Lett 1997, V38; P1511 HCAPLUS
(3) Livant, D; Cancer Res 2000, V60, P309 HCAPLUS
(4) Mould, A; Biochem J 1998, V331, P821 HCAPLUS
(5) Mould, A; J Biol Chem 1997, V272, P17283 HCAPLUS
(6) Pierschbacher, M; Nature 1984, V309, P30 HCAPLUS
(7) Romanovskis, P; J Peptide Res 1998, V52, P356 HCAPLUS
(8) Spatola, A; Terahedron Lett 1996, V37, P591 HCAPLUS
IT **483369-70-6P 483369-71-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of peptidyl hydroxamic acids as potential antitumor and antimetastatic agents)
RN 483369-70-6 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-N-hydroxy-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 483369-71-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-N-hydroxy-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:631705 HCAPLUS
DN 138:297158
ED Entered STN: 22 Aug 2002
TI Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma
AU van Golen, Kenneth L.; Bao, Liwei; Brewer, George J.; Pienta, Kenneth J.; Kamradt, Jeffrey M.; Livant, Donna L.; Merajver, Sofia D.
CS Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, 48109-0948, USA
SO Neoplasia (New York, NY, United States) (2002), 4(5), 373-379
CODEN: NEOPFL; ISSN: 1522-8002
PB Nature Publishing Group
DT Journal
LA English
CC 1-6 (Pharmacology)
AB Plasma fibronectin-mediated invasion of human DU145 prostate cancer cell line was efficaciously inhibited in a rat tumor model by treatment with Ac-PHSCN-NH2 peptide. Invasion of DU145 cells was stimulated by the PHSRN sequence of plasma fibronectin. However, PHSCN acts as a competitive inhibitor of PHSRN-mediated invasion. In the current study, we determined whether PHSCN could inhibit the recurrence and metastasis of DU145 tumors after excision of the primary tumor in an athymic nude mouse model. We demonstrated that mice treated thrice weekly with i.v. Ac-PHSCN-NH2 peptide survived tumor-free for more than 30 wk post-primary tumor excision, whereas their untreated counterparts succumbed to recurrence and/or metastatic disease in significantly less time. Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. Significant reduction in size of the primary tumor was observed in mice rendered copper deficient. We sought to reduce tumor growth at the primary and metastatic sites by combining the anti-invasion Ac-PHSCN-NH2 peptide with TM. Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy.
ST PHSCN peptide antiangiogenic tetrathiomolybdate prostate carcinoma recurrence metastasis
IT Prostate gland, neoplasm
(carcinoma, metastasis; suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)
IT Prostate gland, neoplasm

(carcinoma; suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)
IT Carcinoma
(prostatic, metastasis; suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)
IT Carcinoma
(prostatic; suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)
IT Angiogenesis inhibitors
Antitumor agents
Drug interactions
Human
(suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)
IT 7440-50-8, Copper, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(deficiency; efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model)
IT 16330-92-0 **262438-43-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Allen, M; Hum Pathol 1998, V29, P311 MEDLINE
(2) American Cancer Society; Cancer Facts and Figures 2002
(3) Livant, D; Cancer Res 1995, V55, P5085 HCAPLUS
(4) Livant, D; Cancer Res 2000, V60, P309 HCAPLUS
(5) Mosher, D; Annu Rev Med 1984, V35, P561 HCAPLUS
(6) Nozue, M; Oncol Rep 2001, V8(6), P1247 MEDLINE
(7) Partin, A; Urology 2001, V58, P843 MEDLINE
(8) Rokhlin, O; Prostate 1995, V26, P205 HCAPLUS
(9) Romanov, V; Prostate 1999, V39, P108 HCAPLUS
(10) Schroder, J; Hepatogastroenterology 1998, V45, P1807 MEDLINE
(11) Smith, D; Urol Clin North Am 1999, V26, P323 MEDLINE
(12) Trikha, M; Cancer Res 1996, V56, P5071 HCAPLUS
(13) Uchiyama, A; Br J Cancer 1999, V81(4), P721 MEDLINE
(14) van Golen, K; Clin Exp Metastasis 1996, V14, P95 HCAPLUS
(15) Webber, M; Clin Cancer Res 1995, V1, P1089 MEDLINE
(16) Witkowski, C; J Cancer Res Clin Oncol 1993, V119, P637 HCAPLUS
(17) Zheng, D; Cancer Res 1999, V59, P1655 HCAPLUS
IT **262438-43-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suppression of tumor recurrence and metastasis by a combination of PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma)
RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:555761 HCAPLUS
DN 137:121939
ED Entered STN: 26 Jul 2002
TI Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
IN Livant, Donna
PA The Regents of the University of Michigan, USA
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N-0033/574
ICS A61K-0049/00; A61K-0051/00
CC 9-16 (Biochemical Methods)
Section cross-reference(s): 14
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002057786	A2	20020725	2002WO-US01189	20020115
	WO2002057786	A3	20031211		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2435320	AA	20020725	2002CA-2435320	20020115
	EP---1388013	A2	20040211	2002EP-0713418	20020115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	2001US-0765496	A	20010118		
	2002WO-US01189	W	20020115		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002057786	ICM	G01N-0033/574
	ICS	A61K-0049/00; A61K-0051/00
	IPCI	G01N0033-574 [ICM,7]; A61K0049-00 [ICS,7]; A61K0051-00 [ICS,7]
	IPCR	A61K0051-02 [I,C]; A61K0051-08 [I,A]; G01N0033-50 [I,A]; G01N0033-50 [I,C]; G01N0033-574 [I,A]; G01N0033-574 [I,C]
	ECLA	A61K051/08; G01N033/50D4; G01N033/574V4
CA---2435320	IPCI	G01N0033-574 [ICM,7]; A61K0049-00 [ICS,7]; A61K0051-00 [ICS,7]
EP---1388013	IPCI	G01N0033-574 [ICM,7]; A61K0049-00 [ICS,7]; A61K0051-00 [ICS,7]

IPCR A61K0051-02 [I,C]; A61K0051-08 [I,A]; G01N0033-50 [I,A]; G01N0033-50 [I,C]; G01N0033-574 [I,A]; G01N0033-574 [I,C]

OS MARPAT 137:121939

AB The present invention concerns the detection tumors in vivo, the imaging of tumors in vivo, and the imaging of cancerous tissue in pathol. samples. In particular the present invention incorporates the use of fibronectin fragments into these same detection and imaging methods.

ST fibronectin cancer diagnosis imaging blood culture peptide radioisotope fluorescent

IT Animal tissue
(autopsy sample; compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Radiography
(autoradiography; compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Animal tissue
Blood analysis
Blood plasma
Blood serum
Body fluid
Diagnosis
Epithelium
Fibroblast
Fluorescent substances
Human
Imaging
Mammary gland, neoplasm
Neoplasm
Pathology
Positron-emission tomography
Prostate gland
Rattus
Sample preparation
Scintigraphy
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Peptides, uses
Radionuclides, uses
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Fibronectins
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(degradation products; compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Drug delivery systems
(injections, i.v.; compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Skin
(keratinocyte; compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Culture media
(serum-free; compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT Surgery
(tissue sample; compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT 252229-84-8P
RL: ARG (Analytical reagent use); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT 252230-05-0 262438-43-7 443305-20-2 443305-23-5

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT 252229-85-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)

IT 158622-13-0 252229-04-2 252229-05-3 252229-06-4 252229-07-5
252229-08-6 252229-09-7 252229-10-0 252229-11-1 252229-12-2
252229-13-3 252229-14-4 252229-15-5 252229-16-6 252229-17-7
252229-18-8 252229-19-9 252229-20-2 252229-21-3 252229-22-4
252229-23-5 252229-24-6 252229-25-7 252229-26-8 252229-27-9
252229-29-1 252229-30-4 252229-31-5 252229-32-6 252229-33-7
252229-34-8 252229-35-9 252229-36-0 252229-37-1 252229-38-2
252229-39-3 252229-40-6 252229-41-7 252229-42-8 252229-43-9
252229-44-0 252229-45-1 252229-46-2 252229-47-3 252229-48-4
252229-49-5 252229-50-8 252229-51-9 252229-52-0 252229-53-1
252229-54-2 252229-55-3 252229-56-4 252229-57-5 252229-58-6
252229-59-7 252229-60-0 252229-61-1 252229-63-3 252229-65-5
252229-66-6 252229-67-7 252229-68-8 252229-69-9 252229-70-2
252229-71-3 252229-72-4 252229-73-5 252229-74-6 252229-75-7
252229-76-8 252229-77-9 252229-78-0 252229-79-1 252229-80-4
252229-81-5 252229-82-6 252229-83-7
RL: PRP (Properties)
(unclaimed sequence; compns. and methods for the use of fibronectin fragments in the diagnosis of cancer)

IT **262438-43-7 443305-23-5**
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(compns. and methods for use of fibronectin fragments in diagnosis of cancer)

RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443305-23-5 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-D-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:102218 HCAPLUS
DN 132:245978
ED Entered STN: 13 Feb 2000
TI Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma
AU Livant, Donna L.; Brabec, R. Kaye; Pienta, Kenneth J.; Allen, David L.; Kurachi, Kotoku; Markwart, Sonja; Upadhyaya, Ameet
CS Department of Cell and Development Biology, University of Michigan Medical School, Ann Arbor, MI, 48109-0616, USA
SO Cancer Research (2000), 60(2), 309-320
CODEN: CNREA8; ISSN: 0008-5472
PB AACR Subscription Office
DT Journal
LA English
CC 1-6 (Pharmacology)
AB Using naturally serum-free SU-ECM basement membranes as invasion substrates showed that plasma fibronectin was necessary to stimulate invasion by DU 145 human and metastatic MATLyLu (MLL) rat prostate carcinoma cells. This activity mapped to the PHSRN sequence, which induced invasion through α5β1 integrin. PHSCN, a competitive inhibitor, blocked both PHSRN- and serum-induced invasion. Acetylated, amidated PHSCN (Ac-PHSCN-NH2) was 30-fold more potent; however, Ac-HSPNC-NH2 was inactive. Rats receiving injections s.c. with 100,000 MLL cells were treated systemically by i.v. injection three times weekly with 1 mg of either Ac-PHSCN-NH2 or Ac-HSPNC-NH2 beginning 24 h later, three times weekly with 1 mg of Ac-PHSCN-NH2 beginning only after surgery to remove large (2 cm) MLL tumors, or were left untreated. MLL tumors grew rapidly in Ac-HSPNC-NH2-treated and in untreated rats. MLL tumor growth in rats treated with Ac-PHSCN-NH2 beginning 1 day after MLL cell injection was reduced by 99.9% during the first 16 days of treatment, although subsequent tumor growth occurred. MLL tumor cryosections immunostained with anti-PECAM-1 showed that Ac-PHSCN-NH2 inhibited neovascularization by 12-fold during this time. Whether initiated after MLL cell injection or only after MLL tumor removal, Ac-PHSCN-NH2 treatment reduced the nos. of MLL lung colonies and micrometastases by 40- to > 100-fold, whereas Ac-HSPNC-NH2 was inactive. Thus, Ac-PHSCN-NH2 may be a potent antitumorigenic and antimetastatic agent for postsurgical use prior to extensive metastasis.
ST antitumorigenic antimetastatic PHSCN sequence prostate carcinoma; lung metastasis inhibitor prostate anticancer AcPHSCNNH2
IT Angiogenesis inhibitors
Protein sequences
(anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
IT Prostate gland
Prostate gland
(carcinoma, inhibitors; anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
IT Lung, neoplasm
(inhibitors, metastasis; anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)

IT Antitumor agents
(lung, metastasis; anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
IT Lung, neoplasm
(metastasis, inhibitors; anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
IT Antitumor agents
(prostate carcinoma; anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
IT **262438-43-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Akiyama, S; Cancer Metastasis Rev 1995, V14, P173 HCAPLUS
(2) Akiyama, S; J Biol Chem 1985, V260, P4492 HCAPLUS
(3) Amemiya, S; Dev Growth Differ 1989, V31, P131
(4) Aota, S; J Biol Chem 1994, V269, P24756 HCAPLUS
(5) Atherton, E; Solid Phase Peptide Synthesis: A Practical Approach 1989
(6) Burnette, W; Anal Biochem 1981, V112, P195 HCAPLUS
(7) Carter, H; A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer 1988, P1
(8) Clark, R; The Molecular and Cellular Biology of Wound Repair 1996, P12
(9) de Souza, P; Br J Cancer 1997, V75, P1593 HCAPLUS
(10) Doherty, D; J Clin Invest 1990, V86, P1065 HCAPLUS
(11) Dunning, W; Monogr Natl Cancer Inst 1963, V12, P351 MEDLINE
(12) Elstein, K; Exp Cell Res 1994, V211, P322 HCAPLUS
(13) Flaris, N; GLIA 1993, V7, P34 MEDLINE
(14) Foulkes, E; Metallothionein in Biology and Medicine 1991, P171 HCAPLUS
(15) Fournier, G; Eur Urol 1996, V30(Suppl 1), P32
(16) Hayman, E; J Cell Biol 1979, V83, P255 HCAPLUS
(17) Hayman, E; Methods Enzymol 1982, V82, P803
(18) Huhtala, P; J Cell Biol 1995, V129, P867 HCAPLUS
(19) Humason, G; Animal Tissue Techniques 1972, P34
(20) Humphries, M; Science (Washington DC) 1986, V233, P467 HCAPLUS
(21) Isaacs, J; Prostate 1986, V9, P261 MEDLINE
(22) Iwamoto, Y; Science (Washington DC) 1987, V238, P1132 HCAPLUS
(23) Johansson, S; Br J Cancer 1998, V77, P1213 HCAPLUS
(24) Jungwirth, A; Br J Cancer 1997, V75, P1585 HCAPLUS
(25) Kim, J; Cell 1998, V94, P353 HCAPLUS
(26) Lafarga, M; J Neurosci Methods 1997, V75, P137 HCAPLUS
(27) Litvinovich, S; J Mol Biol 1995, V248, P611 HCAPLUS
(28) Livant, D; Cancer Res 1995, V55, P5085 HCAPLUS
(29) Male, D; Immunology 1995, V84, P453 HCAPLUS
(30) Mant, C; Methods Enzymol 1997, V289, P426 HCAPLUS
(31) Mogford, J; J Clin Investig 1997, V100, P1647 HCAPLUS
(32) Mosher, D; Annu Rev Med 1984, V35, P561 HCAPLUS
(33) Mould, A; J Biol Chem 1997, V272, P17283 HCAPLUS
(34) Newman, P; J Clin Invest 1997, V100(Suppl 11), PS25
(35) Peehl, D; Culture of Epithelial Cells 1992, P159
(36) Pienta, K; J Natl Cancer Inst 1995, V87, P348 HCAPLUS
(37) Pienta, K; Prostate 1992, V20, P233 HCAPLUS
(38) Pinski, J; Cancer Res 1994, V54, P169 HCAPLUS
(39) Pinski, J; Prostate 1993, V23, P165 HCAPLUS
(40) Postlethwaite, A; J Exp Med 1976, V144, P1188 HCAPLUS
(41) Postlethwaite, A; J Exp Med 1981, V153, P494 HCAPLUS
(42) Raghaven, D; Semin Oncol 1988, V15, P371
(43) Reed, G; Manganese in Metabolism and Enzyme Function 1986, P313 HCAPLUS
(44) Roklin, O; Prostate 1995, V26, P205
(45) Rossino, P; Exp Cell Res 1990, V189, P100 HCAPLUS
(46) Saiki, I; Jpn J Cancer Res 1990, V81, P660 HCAPLUS
(47) Schulze, H; Prostate Cancer Part A: Research, Endocrine Treatment, and Histopathology: Progress in Clinical and Biological Research 1987, V243A,

P1 MEDLINE
(48) Silverberg, E; CA Cancer J Clin 1988, V38, P107
(49) Srialovic, G; Endocrinology 1990, V127, P3052
(50) Stone, K; Int J Cancer 1978, V21, P274 MEDLINE
(51) Templeton, N; Cancer Res 1990, V50, P5431 HCAPLUS
(52) Tomaselli, K; J Cell Biol 1988, V107, P1241 HCAPLUS
(53) Von Eschenbach, A; CA Cancer J Clin 1997, V47, P261 MEDLINE
(54) Vukanovic, J; Cancer Res 1995, V55, P1499 HCAPLUS
(55) Wayner, E; J Cell Biol 1988, V107, P1881 HCAPLUS
(56) Wiltbank, M; Biol Reprod 1990, V42, P139 MEDLINE
(57) Witkowski, C; Cancer Res Clin Oncol 1993, V119, P637 HCAPLUS
(58) Zar, J; Biostatistical Analysis 1984, P138
IT 262438-43-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma)
RN 262438-43-7 HCAPLUS
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> b uspatall
FILE 'USPATFULL' ENTERED AT 07:02:45 ON 11 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 07:02:45 ON 11 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l29 1-2

L29 ANSWER 1 OF 4 USPATFULL on STN
AN 2005:240102 USPATFULL
TI Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
IN Schultz, Clyde L., Ponte Vedra, FL, UNITED STATES
PI US2005208102 A1 20050922
AI 2004US-0821718 A1 20040409 (10)
PRAI 2003US-461354P 20030409 (60)
DT Utility
FS APPLICATION
LREP FINCH IP LLC, P.O. BOX 1358, CONCORD, NH, 03302, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 502
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a

dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 262438-43-7, ATN-161
(hydrogels containing drugs for treatment of eye diseases in posterior segment)
RN 262438-43-7 USPATFULL
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 2 OF 4 USPATFULL on STN
AN 2005:87035 USPATFULL
TI Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
IN Schultz, Clyde L., Ponte Vedra, FL, UNITED STATES
PI US2005074497 A1 20050407
AI 2004US-0971997 A1 20041022 (10)
RLI Continuation-in-part of Ser. No. 2004US-0821718, filed on 9 Apr 2004, PENDING
PRAI 2003US-461354P 20030409 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Exemplary drugs are anti-angiogenesis compounds for the treatment of macular degeneration. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 262438-43-7, ATN-161
(hydrogels containing drugs for treatment of eye diseases in posterior segment)
RN 262438-43-7 USPATFULL

CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs fhitstr l29 3-4

L29 ANSWER 3 OF 4 USPATFULL on STN
AN 2005:24260 USPATFULL
TI Peptides which target tumor and endothelial cells, compositions and uses thereof
IN Ternansky, Robert J., San Diego, CA, UNITED STATES
Allan, Amy L., Encinitas, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Yoon, Won Hyung, San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Mazar, Andrew, San Diego, CA, UNITED STATES
PI US2005020810 A1 20050127
AI 2003US-0722843 A1 20031125 (10)
PRAI 2002US-429174P 20021125 (60)
2003US-475539P 20030602 (60)
DT Utility
FS APPLICATION
LREP Sunil K. Singh, Dorsey & Whitney LLP, Intellectual Property Department, Four Embarcadero Center, Suite 3400, San Francisco, CA, 94111-4187
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to peptide analogs of Ac--PHSCN--NH.sub.2 which target tumor and endothelial cells and have anti-tumor, anti-angiogenic and anti-metasastic activity, methods of making these peptides, compositions thereof and methods of using these peptides and pharmaceutical compositions thereof to treat, prevent and detect diseases characterized by tumor growth, metastasis and angiogenesis. The peptide analogs may serve, inter alia, as carriers of radioactivity, PET-active compounds, toxins, fluorescent molecules and PEG molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **701200-82-0P**
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
RN 701200-82-0 USPATFULL
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-[(4-methylphenyl)methyl]-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 4 OF 4 USPATFULL on STN
AN 2004:209805 USPATFULL
TI Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
IN Allan, Amy L., Encinitas, CA, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Hopkins, Stephanie A., Poway, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Mazar, Andrew, San Diego, CA, UNITED STATES
O'Hare, Sean M., San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Plunkett, Marian, San Diego, CA, UNITED STATES
Ternansky, Robert J., San Diego, CA, UNITED STATES
Yoon, Won Hyung, San Diego, CA, UNITED STATES
PI US2004162239 A1 20040819
AI 2003US-0723144 A1 20031125 (10)
PRAI 2002US-429174P 20021125 (60)
2003US-475539P 20030602 (60)
DT Utility
FS APPLICATION
LREP COOLEY GODWARD, LLP, 3000 EL CAMINO REAL, 5 PALO ALTO SQUARE, PALO ALTO, CA, 94306
CLMN Number of Claims: 65
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 3373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **701200-82-0P**
(peptide inhibitors of angiogenesis, cell migration, cell invasion and cell proliferation, preparation, and compns. and therapeutic uses)
RN 701200-82-0 USPATFULL
CN L-Aspartamide, 1-acetyl-L-prolyl-L-histidyl-L-seryl-S-[(4-methylphenyl)methyl]-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 06:38:43 ON 11 MAY 2006)

FILE 'HCAPLUS' ENTERED AT 06:39:05 ON 11 MAY 2006

L1	3	US2004162239/PN OR (US2003-723144 OR US2002-429174# OR US2003-4
		E TERNANSKY R/AU
L2	61	E4-8
		E TERNANSKY B/AU
		E HOPKINS S/AU
L3	42	E3-4
		E HOPKINS STEPHANIE/AU
L4	9	E3-6
		E YOON W/AU
L5	15	E3,E6
		E YOON WON/AU
L6	10	E12
		E YOON WONHYING/AU
		E YOON WONHYUNG/AU
		E ALLAN A/AU
L7	36	E3,E11
		E ALLAN AMY/AU
L8	6	E5
		E GLADSTONE P/AU
L9	28	E3-7
		E OHARE S/AU
		E O HARE S/AU
L10	4	E3,E5
		E O HARE SEAN/AU
L11	8	E3-5
		E DONATE F/AU
L12	28	E3-4,E6
		E MAZAR A/AU
L13	79	E3-4,E7-9
		E PARRY G/AU
L14	181	E3-14
		E PARRY GRAHAM/AU
L15	43	E3-5
		E PLUNKETT M/AU
L16	24	E3-7
		E ATTENTION/CS,PA
L17	15	E3,E5-6
		E ATTENUON/CS,PA

```
L18          23 ATTENUON/CS,PA

     FILE 'REGISTRY' ENTERED AT 06:45:13 ON 11 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 06:45:19 ON 11 MAY 2006
L19             TRA L1 1- RN :     209 TERMS

     FILE 'REGISTRY' ENTERED AT 06:45:19 ON 11 MAY 2006
L20         209 SEA L19
L21             STR
L22             STR L21
L23           3 L22 CSS
L24          64 L22 CSS FULL
                SAV TEM L24 GAR144F0/A

     FILE 'HCAPLUS' ENTERED AT 06:59:28 ON 11 MAY 2006
L25           8 L24
L26           3 L25 AND L1-18
L27           5 L25 NOT L26

     FILE 'HCAOLD' ENTERED AT 07:00:13 ON 11 MAY 2006
L28           0 L24

     FILE 'USPATFULL, USPAT2' ENTERED AT 07:00:33 ON 11 MAY 2006
L29           4 L24

=>
```